Guest Editorial Congress must commit to sustained increases for NCI March 29, 2019Vol.45 No.13By Brian Higgins and Peter King
Cancer is a model for drug development, FDA-bound Sharpless says to NCI advisors March 29, 2019Vol.45 No.13By Paul Goldberg
FreeGuest Editorial NCCN validates path toward de-escalated doses and reduced costs of cancer drugs March 29, 2019Vol.45 No.13By Allen S. Lichter, Mark J. Ratain, Leonard B. Saltz, Michael Stebbins and David Hyman
Texas cancer researchers vying to renew CPRIT beyond its 2023 sunset dateThe institute is spending more than NCI in the state March 22, 2019Vol.45 No.12By Claire Dietz and Matthew Bin Han Ong
FreeTrials & Tribulations SWOG’s 1501 study takes aim at the silo wall between cardiology and oncology March 22, 2019Vol.45 No.12By Justin Floyd
Conversation with The Cancer Letter James Willson: CPRIT is money well spent March 22, 2019Vol.45 No.12By Claire Dietz and Matthew Bin Han Ong
Conversation with The Cancer LetterFree TMIST PI Pisano: “Are we further reducing breast cancer mortality the more intensively we screen?” March 15, 2019Vol.45 No.11By Paul Goldberg
Hortobagyi to deliver Karnofsky lecture; Brugge–Science of Oncology lecture; Wolmark–Gianni Bonadonna lecture March 15, 2019Vol.45 No.11
